| Inducer |
Treatment |
AGEs IC50 (µM) |
| Glucose |
1 |
619 ± 8.32a*** |
| 2 |
593 ± 7.45b |
| 3 |
545 ± 10.43 |
| 4 |
712 ± 15.21c** |
| 5 |
1003 ± 25.28c* |
| 6 |
815 ± 7.87 a** |
| 7 |
1065 ± 23.65 c* |
| 8 |
512 ± 18.23 |
| Aminoguanidine |
482 ± 43.21 |
| Phloroglucinol |
553 ± 29.42 |
| Methylglyoxal |
1 |
1169 ± 12.45 a |
| 2 |
1032 ± 21.67 |
| 3 |
986 ± 19.54 |
| 4 |
1305 ± 46.28 b** |
| 5 |
1701 ± 52.34 a** |
| 6 |
1659 ± 48.64 c*** |
| 7 |
1824 ± 38.90 b* |
| 8 |
875 ± 19.76 |
| Aminoguanidine |
910 ± 20.37 |
| Phloroglucinol |
1019 ± 32.48 |
| |
|
% |
| Lysozyme/ribose |
1 |
47.2 ± 5.43 c |
| 2 |
51.9 ± 4.86 |
| 3 |
57.7 ± 3.98 |
| 4 |
42.5 ± 4.65 a |
| 5 |
36.3 ± 4.75 a |
| 6 |
30.9 ± 1.98 b |
|
7 |
29.8 ± 3.56 a |
| 8 |
60.3 ± 2.74 |
| Pyridoxamine |
58.3 ± 5.10 |
Data are mean ± standard deviation of triplicate tests. The fluorescence intensity
was measured at ex 370 nm and em 470 nm. The intensity of each blank was
subtracted from the intensity of each sample. Concentration of an inhibitor required
to inhibit 50% of the control. Calculated from linear regression equation. ap<0.05,
bp<0.01, cp< 0.001; vs control aminoguanidine or *p<0.05, **p<0.01, ***p<0.001; vs
control controlphloroglucinol or orpyridoxamine n. |
